Expert Perspectives & Insights into the Evolving Treatment of Refractory Metastatic Colorectal Cancer : Episode 3
Fruquintinib MoA and Toxicity Profile Overview
Key safety considerations for the use of fruquintinib are explored.
EP: 1.Overview of Current mCRC Treatment Landscape
EP: 2.Evaluating 3L Treatment Landscape Evolution
Now Viewing
EP: 3.Fruquintinib MoA and Toxicity Profile Overview
EP: 4.Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
EP: 5.FRESCO-2 Study Highlights
EP: 6.Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
EP: 7.Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
EP: 8.Consideration for Fruquintinib Dosing and Titration
EP: 9.Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies
EP: 10.Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
EP: 11.Considerations for Platinum-based Therapy
EP: 12.Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
EP: 13.Real-World Data Surrounding Sequencing Strategies for Refractory mCRC
EP: 14.Data Surrounding Treatment for MSI-high Patients from ASCO 2024
EP: 15.Unmet Needs Surrounding mCRC Treatment
EP: 16.Anticipating Key Studies and Pipeline Treatments in mCRC Landscape
Related Videos
Related Content
